Alivus Life Sciences Ltd (ALIVUS)
₹1,415.30
Mkt cap
₹17,376 Cr
P/E ratio
25.20
P/B
4.78
Div yield
0.35%
ROE
17.90%
ROCE
23.80%
EPS (TTM)
₹56.16
Book value
₹296
52W range
819–1,499
Sector
Healthcare
Price history
Previous close
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
NSE ALIVUSBSE 543322
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−5.58% from high₹1,415
₹819+72.81% from low₹1,499
Current
₹1,415.30
Prev close
₹1,397.40
Day
+1.28%
Price performance
1D
+0.54%
1W
+12.35%
1M
+3.55%
3M
+28.23%
6M
+39.73%
1Y
+52.53%
YTD
+55.02%
Financials
Revenue, profit & margin
P/E ratio
25.2×
ALIVUS is 27% below the sector median of 34.4×
ALIVUS25.2×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 | 682 | |
| Expenses | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 | 417 | |
| Operating Profit | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 | 265 | |
| OPM % | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% | 39% | |
| Other Income | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 | 20 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Depreciation | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 | 22 | |
| Profit before tax | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 | 262 | |
| Tax % | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% | 25% | |
| Net Profit | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 | 197 | |
| EPS in Rs | 9.69 | 9.69 | 7.99 | 9.10 | 7.78 | 11.18 | 11.58 | 9.91 | 10.60 | 12.25 | 13.25 | 13.04 | 16.03 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.10% · closed higher next day 10 of last 20
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 23 Jan '24◦ | 25 Apr '24◦ | 25 Jul '24◦ | 24 Oct '24◦ | 23 Jan '25◦ | 15 May '25◦ | 1 Aug '25◦ | 6 Nov '25◦ | 22 Jan '26 | 14 May '26◦ | 30 Jul '26◦ | 29 Oct '26◦ |
| Earnings day | +1.18% | +8.59% | −2.92% | −9.86% | −1.52% | −5.26% | −3.49% | +2.76% | +0.02% | −1.83% | +5.87% | +0.54% |
| +1 day | +5.82% | +9.15% | −0.63% | −5.95% | +2.62% | −5.10% | −1.39% | +3.38% | +2.58% | −0.83% | +10.83% | — |
| +5 days | +8.42% | +10.72% | +0.88% | +3.11% | +2.85% | −7.38% | −7.32% | +1.59% | +11.58% | −2.36% | +21.37% | — |
| +15 days | +10.82% | +9.60% | +13.46% | +4.02% | −12.07% | −16.58% | −5.21% | +0.90% | +6.79% | −5.84% | +23.29% | — |
| +30 days | −3.13% | +16.79% | +37.51% | +0.85% | −7.54% | −16.97% | −6.16% | +1.14% | +6.79% | +8.68% | +26.57% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202674.85%Promoter
Promoters74.85%0.02
FIIs5.93%0.39
DIIs7.03%0.15
Public12.19%0.23
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Alivus Life | ₹1,415.30 | 25.24 | 17,376 | 0.35% | 197 | +51.31% | 682 | +15.99% | 23.79% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports6
Concall transcripts49
PPTOct 2026RECOct 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptOct 2024PPTOct 2024RECOct 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 30 Oct - Alivus Life Sciences schedules one-on-one investor meetings in Mumbai on November 4 and 6, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Oct - Uploaded Q2 FY2027 earnings call audio recording on October 30, 2026.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 29 Oct - Intimation with respect to allotment of equity shares under "Employee Stock Option Scheme, 2021"Announcement under Regulation 30 (LODR)-Investor Presentation 29 OctAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 29 Oct - Alivus Life Sciences reported Q2FY27 revenue up 16%, EBITDA margin 41.8%, and capex progress at Solapur and Taloja.